AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04298697
Drug: Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.
Trial: NCT04268888
Drug: Nivolumab and TACE/TAE
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Immunotherapy and TACE/TAE
Trial: NCT02673372
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
Trial: NCT02673372
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
Trial: NCT00392353
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT00392353
Drug: Vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04263623
Drug: Dexmecamylamine HCl
RxNorm normalized name: Mecamylamine Hydrochloride
DrugBank: Dexmecamylamine (DB11807)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug
Trial: NCT00352768
Drug: Fluvoxamine maleate
RxNorm normalized name: Fluvoxamine Maleate
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
Trial: NCT02780128
Drug: Ribociclib
RxNorm normalized name: Ribociclib
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will take ribociclib once per day orally for Days 1-21 of a 28-day cycle.
Trial: NCT02780128
Drug: Ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will take ceritinib once per day orally for 28 days of a 28-day cycle.
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 0.3 mg, once daily, 1 day
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 1.0 mg, once daily, 1 day
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 3 mg, once daily, 1 day
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 10 mg, once daily, 1 day
Trial: NCT01498068
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 30 mg, once daily, 1 day
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral , 75 mg, once daily, 1 day
Trial: NCT01498068
Drug: Pegylated-interferon-alfa-2a
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
Trial: NCT01498068
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is \< 75kg) or 1200mg (if participant's weight is \>= 75kg) per day for 24 or 48 weeks.
Trial: NCT01054014
Drug: JNJ-40346527/Placebo
DrugBank: JNJ-40346527 (DB12504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
Trial: NCT01054014
Drug: JNJ-40346527/Placebo
DrugBank: JNJ-40346527 (DB12504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
Trial: NCT01054014
Drug: JNJ-40346527
RxNorm normalized name: JNJ-40346527
DrugBank: JNJ-40346527 (DB12504)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
Trial: NCT02474316
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
Trial: NCT02474316
Drug: nucleos(t)ide analgoue
RxNorm normalized name: T-5224
DrugBank: T-5224 (DB05998)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
Trial: NCT01855529
Drug: Ropivacaine in one arm and placebo (NaCl) in the other arm
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00549146
Drug: fluticasone propionate/salmeterol 250/50 DISKUS combination product
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00549146
Drug: fluticasone propionate DISKUS 500mcg
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01521117
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 150 mg, once daily, 1 day
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral Solution, Oral, 300 mg, once daily, 1 day
Trial: NCT03361800
Drug: Entinostat
RxNorm normalized name: entinostat
DrugBank: Entinostat (DB11841)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral drug, 5mg tablet given once weekly x 2 doses
Trial: NCT03923166
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg qd
Trial: NCT01105429
Drug: BMS-820132
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, (TBD), once daily, 2 days
Trial: NCT00771758
Drug: oxycodone IR
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: maximum daily dose 450 mg
Trial: NCT00771758
Drug: tapentadol IR
DrugBank: Tapentadol (DB06204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
Trial: NCT04065269
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATR inhibitor
Trial: NCT04065269
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PARP inhibitor
Trial: NCT04065269
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-PD-L1 immunotherapy
Trial: NCT04432584
Drug: Crovalimab
RxNorm normalized name: Crovalimab
DrugBank: Crovalimab (DB16128)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.
Trial: NCT04432584
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
Trial: NCT00522093
Drug: TJ-100
RxNorm normalized name: TJ-CD4B/ABL111
DrugBank: Givastomig (DB18618)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ-100 2.5g three times per day for 6 weeks
Trial: NCT03534804
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib is administered at 40 mg oral daily
Trial: NCT03534804
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab will be administered at a fixed dose of 200mg intravenously every 3 weeks.
Trial: NCT00000336
Drug: Selegiline
RxNorm normalized name: Selegiline
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03413891
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mouthwash
Trial: NCT02185729
Drug: Intralipid
RxNorm normalized name: Intralipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of Intralipid (soybean-derived fat)
Trial: NCT02185729
Drug: ClinOleic
RxNorm normalized name: linoleate
DrugBank: Cholesteryl Linoleate (DB02092)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of ClinOleic (olive oil-based)
Trial: NCT02185729
Drug: Dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of dextrose (sugar) without fat
Trial: NCT03420963
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04172506
Drug: AK105
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibody
Trial: NCT06795698
Drug: Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin 1mg/kg of ideal body weight subcutaneous every 24 hours in patients with eGFR \<30ml/min/1.73m2
Trial: NCT01248923
Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 1: standard of care; Part 2: standard of care determined in Part 1.
Trial: NCT01248923
Drug: Dexamethasone, steroid; oral
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part 1: standard of care; Part 2: standard of care determined in Part 1.
Trial: NCT01248923
Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 1: standard of care; Part 2: standard of care.
Trial: NCT01248923
Drug: Bortezomib, proteasome inhibitor; intravenous or subcutaneous
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 1: standard of care
Trial: NCT01248923
Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Part 1: standard of care
Trial: NCT02320084
Drug: Nitisinone
RxNorm normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nitisinone according to prescription
Trial: NCT02086175
Drug: Imprime PGG
RxNorm normalized name: Imprime PGG
DrugBank: Odetiglucan (DB17468)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02086175
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03132532
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03132532
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03132532
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03132532
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemotherapy
Trial: NCT03132532
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Chemotherapy
Trial: NCT00208702
Drug: Triiodothyronine
RxNorm normalized name: Triiodothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00208702
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03417102
Drug: fitusiran
RxNorm normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection; by subcutaneous (SC) injection
Trial: NCT03215069
Drug: Empagliflozin 10 MG
RxNorm normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin 10 mg PO daily
Trial: NCT03624543
Drug: CFI-400945
RxNorm normalized name: Cfi-400945 free base
DrugBank: Ocifisertib (DB18746)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32mg; 28 day cycles; Cycle 1: Days 1-7 then 15-21 Cycle 2 onward: Daily
Trial: NCT03417102
Drug: Bypassing agents
RxNorm normalized name: factor VIII inhibitor bypassing activity
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for injection; by intravenous (IV) injection
Trial: NCT03757936
Drug: HLX04
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection
Trial: NCT03757936
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection
Trial: NCT02891447
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intraperitoneally
Trial: NCT02891447
Drug: Hyperthermic Intraperitoneal Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo HIPEC
Trial: NCT00739648
Drug: MP-376
RxNorm normalized name: 6 MP
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
Trial: NCT02891447
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intraperitoneally
Trial: NCT02099864
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT02662374
Drug: 3% Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ml of the drug in the form of a prepared solution to be swished four times a day
Trial: NCT04009343
Drug: Dihydroartemisinin-piperaquine
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will receive dihydroartemisinin-piperaquine (40/320 mg) dosed according to weight (5 to \<8 kg: 1/2 tablet, 8 to \<11 kg: 3/4 tablet, 11 to \<17 kg: 1 tablet, 17 to \<25 kg: 1 1/2 tablets) at 0, 24, and 48 hours. Medications will be administered according to the manufacturer's instructions.
Trial: NCT02662374
Drug: Nystatin 10000U/ml
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5ml of the drug in mouthwash form to be swished and swallowed four times a day
Trial: NCT04402489
Drug: MT-7117 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MT-7117 Low Dose
Trial: NCT04402489
Drug: MT-7117 High Dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT-7117 High Dose
Trial: NCT03164291
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
Trial: NCT04315948
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
Trial: NCT04315948
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).
Trial: NCT04315948
Drug: Interferon Beta-1A
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
Trial: NCT04315948
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
Trial: NCT04315948
Drug: AZD7442
RxNorm normalized name: AZD7442
DrugBank: AZD7442 (DB15787)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
Trial: NCT04410978
Drug: Tolebrutinib
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT04410978
Drug: Teriflunomide HMR1726
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT04410978
Drug: Placebo to match Tolebrutinib
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT04410978
Drug: Placebo to match Teriflunomide
RxNorm normalized name: Teriflunomide
DrugBank: Teriflunomide (DB08880)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Trial: NCT03229512
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical 1% Sildenafil Cream
Trial: NCT02651038
Drug: Micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Measurement of PK
Trial: NCT00113321
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 IV over 1 hour daily x 5 days.
Trial: NCT02978339
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.